News Posts List
Bristol-Myers Squibb and Five Prime Therapeutics Announce Exclusive Clinical Collaboration to Evaluate the Combination of Investigational Immunotherapies Opdivo (nivolumab) and FPA008 in Six Tumor Typ
11/25/2014
Bristol-Myers Squibb Company (NYSE:BMY) and Five Prime Therapeutics, Inc. (Nasdaq:FPRX) today announced that they have entered into an exclusive clinical collaboration agreement to evaluate the safety, tolerability and preliminary efficacy of combining Opdivo (nivolumab), Bristol-Myers Squibb’s investigational PD-1 (programmed death-1) immune checkpoint inhibitor, with FPA008, Five Prime’s monoclonal antibody that inhibits colony stimulating factor-1 receptor (CSF1R).
'Surrogate measures' win FDA approval for cancer drugs without proof they help save lives
11/24/2014
The drug designed to keep him alive may have hastened his death
Immunotherapy set to revolutionise cancer treatment
11/24/2014
Immunotherapy is set to revolutionise the treatment of cancer, according to ESMO President Professor Rolf A. Stahel
Survival trends among patients with advanced renal cell carcinoma
11/21/2014
nce the approval of sorafenib in December 2005, several targeted therapeutic agents have been approved by the FDA for the treatment of advanced renal cell carcinoma (RCC).
Statin use linked to improved RCC surgery outcomes
11/19/2014
Statin use at the time of surgery is associated with improved overall survival (OS) and disease-specific survival (DSS) in patients with renal cell carcinoma (RCC) of any stage, US researchers report.
Patients with advanced papillary kidney cancer respond well to a drug combination
11/19/2014
Researchers have found that patients with an advanced form of kidney cancer, for which there is no standard treatment and a very poor prognosis, respond well to a combination of two existing anti-cancer drugs.
Kidney Cancer Association Ranked In Top 2% Of US Charities
11/17/2014
The KCA has earned its seventh consecutive 4-star rating from Charity Navigator
Kidney Cancer Association Patient and Survivor Conference to be Held in North Carolina December 13, 2014
11/14/2014
The University of North Carolina will be hosting its second conference for kidney cancer patients and their families on Saturday, December 13, 2014.
Genentech® Access To Care Foundation Announces Changes to Eligibility Criteria
11/11/2014
The Genentech Access to Care Foundation (GATCF), which provides Genentech medicines for free to people without insurance, is changing its eligibility criteria with the goal of helping more people who may be having trouble accessing Genentech medicines.
Positive Opdivo Phase II Study
11/11/2014
Data from the study will be presented during the Plenary Session at the 2014 Chicago Multidisciplinary Symposium on Thoracic Oncology.
News Feed